Study Group: Obesity Endocrinologists (US)(?)
Council Members in this Study Group: 79
Request a survey with this Study Group
Leading Experts in this Study Group
Joseph Bass, MD, PhD
Division Head of Endocrinology and Metabolism
Evanston Northwestern Healthcare
Joseph Bass, MD, PhD, is Assistant Professor of Medicine and Neurobiology at Northwestern University in Illinois and Division Head of Endocrinology and Metabolism at Evanston Northwestern Healthcare. He is also the Director of a federally-funded basic research program on obesity, diabetes, and lipid...
Harold Bays, MD, FACPPresident and Medical Director
L-MARC Research Center
Harold Bays, MD, FACE, FACP, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all marketed lipid-altering drug treatments, as well...
Farhad Zangeneh, MDAssistant Clinical Professor of Medicine
THE GEORGE WASHINGTON UNIVERSITY - CC
Farhad Zangeneh, MD, is an Assistant Clinical Professor of Medicine at George Washington University School of Medicine in District of Columbia. He is on the board of directors of ACCE and recently contributed to the AACE Diabetes guidelines. He is the Medical Director of Endocrine, Diabetes and Osteoporosis...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
Simply put, there's no incentive to be "emotionally supportive". In primary care, establishing a long term relationship between provider and patient evolves into a trusting relationship. Without the trust part, patient encounters are hollow, theatrical, and not supportive. There is no incentive to either...
Third party payers benefit the most from EHRs because it makes charts easier to audit The cost of implementing an EHR is excessive for a small practice of 2-5 physicians.
The article did not focus on insulin. This is the hormonoal bad guy. Numerous studies looking at sulfonoureas vs glucophage, alpha-glucosidase inhibitors (Acarbose, etc) clearly demonstrate this. If you want real insight into the failures of this study and why, talk with me. Thomas...
I am a heavy user of ARB's and Tekturna. This article does not really show anything of significance. Most practicing physicians have seen much better results and much better tolerability with ARB's than diuretics. I do not think this is going to change prescribing habits of anyone. ...
The article shows that Taranabant is promising anti-obesity drug that may have better luck with the FDA than Rimonabant. Although the trial results are excellent, the company removed higher doses from future trials! What we should learn from Rimonabant failure and Exenatide success?
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Owner
- Partner
- Physician - Division Head
- Director
- President
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms